First Hawaiian Bank Dynavax Technologies Corp Transaction History

First Hawaiian Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 06, 2022	SELL	$9.75 - $14.44 $243,116 - $360,061	-24,935 Closed	0 $0
Q4 2021 Jan 12, 2022	SELL	$13.17 - $20.94 $252,666 - $401,733	-19,185 Reduced 43.48%	24,935 $351,000
Q3 2021 Oct 12, 2021	BUY	$9.16 - $19.83 $133,690 - $289,418	14,595 Added 49.43%	44,120 $848,000
Q2 2021 Jul 08, 2021	SELL	$7.25 - $10.99 $16,240 - $24,617	-2,240 Reduced 7.05%	29,525 $291,000
Q1 2021 Apr 09, 2021	SELL	$4.57 - $11.18 $7,654 - $18,726	-1,675 Reduced 5.01%	31,765 $312,000
Q4 2020 Jan 12, 2021	SELL	$3.73 - $5.6 $5,688 - $8,540	-1,525 Reduced 4.36%	33,440 $149,000
Q3 2020 Oct 06, 2020	BUY	$4.32 - $11.7 $151,048 - $409,090	34,965 New	34,965 $151,000

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

Stay updated on First Hawaiian Bank with notifications on news.